Reception & Kiosk Session
Diabetes Research and Innovation in Canada
May 12, 2014, Parliament Hill, Ottawa
Researchers from across Canada presented their findings to parliamentarians on May 12, 2014. The event was attended by over 40 parliamentarians drawn from all four parties represented in the House and Senate. Other guests including the President of Genome Canada, senior VPs from CIHR, CFI, many CEOs of national health organizations including the JDRF and the Canadian Diabetes Association along with university VPs and political staff from all three major parties. In all, over 120 people attended. Keynote remarks were given by Dr. David Hill and Dr. André Carpentier. Please visit the pages for each of the presenters to learn more about the research presented.
Over three million Canadian children, adolescents, and adults live with some form of diabetes. Millions more with pre-diabetes, are at considerable risk.
The good news is that Canadian researchers are making advances in both our understanding of the disease and its management. New technologies offer hope for better management and monitoring of blood sugar.
Policy makers at federal and local levels and health officials in communities across Canada are in a position to strengthen and coordinate efforts to support further advances through research and improve the risk factors among all Canadians.
Thank you to our Platinum Sponsor
Sanofi Canada is the Canadian affiliate of Sanofi, one of the world’s leading healthcare companies. As a leading healthcare partner, we provide medicines in several therapeutic areas, mainly diabetes, oncology and cardiovascular disease. Backed by decades of service to Canadian healthcare professionals and patients, we are partnering with our customers in the search for solutions to Canada’s healthcare challenges. These include innovative initiatives to promote the appropriate use of medicines, make healthcare more efficient and cost-effective, and help people better manage their health. Other Sanofi entities in Canada include Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases and multiple sclerosis) and Merial (animal health). Together we employ close to 1,700 people across the country. In 2013, Sanofi companies invested $125.1 million in R&D in Canada, creating jobs, business and opportunity throughout the country.
And Our Gold Sponsors:
|AstraZeneca is a leading research-based biopharmaceutical company focused on pushing the boundaries of science and innovation to deliver life-changing medicines — primarily in the areas of cancer, cardiovascular/metabolic disease and respiratory, inflammatory and autoimmune disease.The company’s Canadian Clinical Study Team is involved in more than 60 clinical research projects involving 3,000 Canadian patients. Very recently, the team has taken on leadership for a number of important global Phase III clinical programs, including the study of new molecules for the treatment of patients with severe, uncontrolled asthma and patients with non-small cell lung cancer.||Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents more than 50 member companies investing an excess of $1 billion in research and development each year to fuel Canada’s knowledge-based economy, contributing over $3 billion to the Canadian economy.|